Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05422755
Other study ID # DW_EPOC01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 30, 2019
Est. completion date November 30, 2020

Study information

Verified date July 2022
Source PT. Daewoong Infion
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The study was conducted to assess safety and immunogenicity of recombinant human erythropoietin (rhEPO) manufactured by Daewoong Pharmaceutical Co., Ltd was similar to biological products approved by the drug safety regulatory authority.


Description:

This study consisted of a screening period (4 weeks) and treatment period (52 weeks). Evaluation for immunogenicity effect using ADA (Anti Drug Antibody) detection will be done at weeks 0, 24, and 52 and blood sampling for Routine Hematological tests as supporting data will be conducted every month following hospital regulation. For each subject, the end of the study is the last day of the Blood sample will be drawn In the case of a subject that has left the study (withdrawn), the exit date will be the end of the study. The safety evaluation was conducted based on the incidence of the adverse events local and systemic reactions.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date November 30, 2020
Est. primary completion date November 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who have anemia associated with Chronic Kidney Disease (CKD) under hemodialysis treatment. - Male or female patients aged =18 years. - Patients with mean Hb concentration when screening is around =10 g/dL. - Patients on stable, adequate dialysis for at least three months (defined as no clinically relevant changes of hemodialysis regimen and/or 23/42 ©EMEA 2007 dialyzer). - Has ever been using Epodion treatment in the at least last 1 month. - Haemodialysis patients who likely to remain on Epodion treatment for 52 weeks. - Informed consent given in a written form after being provided with detailed information about the nature, risks, and scope of the clinical trial as well as the expected desirable and adverse effects of the drug. Exclusion Criteria: - History of Pure Red Cell Aplasia (PRCA) or anti-epoetin antibodies. - Contraindications for ESA therapy. - Systemic immunosuppressive medication or any other drugs known to adversely affect the hemoglobin level. - History of uncontrolled hypertension (defined as systolic blood pressure =180 mmHg or diastolic blood pressure =110 mmHg during screening). - Any blood transfusion within the last 2 weeks prior to screening period. - Major surgery within 3 months prior to screening period. - Myelodysplastic syndrome. - History bleeding disorders (e.g. Hemophilia, Von Willebrand, and any conditions that result when the blood cannot clot properly). - Known bone marrow fibrosis (osteitis fibrosa cystica). - Known epilepsy. - Liver cirrhosis with clinical evidence of complications (portal hypertension, splenomegaly, ascites). - Systemic lupus erythematosus. - Previously diagnosed with HIV or acute hepatitis infection. - History of malignancy of any organ system within the last 5 year. - Pregnancy or lactation period in female patients. - Heavy smoker (who smoke over 20 cigarettes daily in average).

Study Design


Locations

Country Name City State
Indonesia Gatot Soebroto Army Hospital Jakarta DKI Jakarta

Sponsors (2)

Lead Sponsor Collaborator
PT. Daewoong Infion Equilab International

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Anti-Erythropoietin Antibodies (ADA) formation at week 52nd to evaluate if there is any incidence of ADA formation on the blood sample week 52
Primary Neutralizing Antibodies detection (Nab) (will be assessed if ADA is positive). to evaluate the neutralizing effect of the detected ADA using cell-based assay method to confirm the impact of the antibody to pharmacological activity. week 52
Secondary Any Adverse Event to evaluate any adverse event related to the test product during study 52 weeks
Secondary Incidence of Anti-Erythropoietin Antibodies (ADA) formation at week 24th to evaluate if there is any incidence of ADA formation on the blood sample week 24
Secondary Comparison on the incidence of Anti-Erythropoietin Antibodies (ADA) formation at week 24th and week 52nd. to evaluate the neutralizing effect of the detected ADA using cell-based assay method to confirm the impact of the antibody to pharmacological activity. week 24 and 52
See also
  Status Clinical Trial Phase
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Recruiting NCT04064827 - A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) Phase 3
Completed NCT02218099 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease Phase 1/Phase 2
Completed NCT02276742 - Lifestyle Management of CKD in Obese Diabetic Patients N/A
Completed NCT01222234 - Impact of Vitamin D Therapies on Chronic Kidney Disease N/A
Recruiting NCT05106387 - An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive A Kidney Transplant
Completed NCT05373303 - The Clinical Study for Evaluating The Safety And Efficacy Of Epodion® N/A
Completed NCT01247311 - Vitamin D and the Health of Blood Vessels in Kidney Disease N/A
Completed NCT04042350 - Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis
Completed NCT02733328 - Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
Completed NCT02341664 - Patient and Provider Assessment of Lipid Management Registry
Enrolling by invitation NCT06322641 - A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists
Completed NCT05755373 - A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists
Completed NCT02678000 - Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function Phase 2
Completed NCT02185911 - Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis N/A
Terminated NCT03226899 - A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment Phase 4
Completed NCT02504294 - A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis Phase 3
Active, not recruiting NCT04094831 - Community-based Screening of Chronic Kidney Disease (CKD) and Measure the Impact of Health Education N/A
Completed NCT01810939 - A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) Phase 3
Enrolling by invitation NCT06447038 - Pilot Study for the Early Detection of Chronic Kidney Disease, Non-Dialysis Objective (NDO).